REGN Quote, Financials, Valuation and Earnings

Gilead Sciences, Inc. has a net margin of 38.89% compared to Regeneron Pharmaceuticals, Inc.'s net margin of 39.21%. Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37% beat Gilead Sciences, Inc.'s return on equity of 41.48%.

Regeneron Pharmaceuticals, Inc. has a consensus price target of $789.90, signalling upside risk potential of 0.6%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $132.38 which suggests that it could grow by 5.74%. Given that Gilead Sciences, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Gilead Sciences, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

Regeneron Pharmaceuticals, Inc. has a beta of 0.369, which suggesting that the stock is 63.095% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.175%.

Regeneron Pharmaceuticals, Inc. has a quarterly dividend of $0.88 per share corresponding to a yield of 0.45%. Gilead Sciences, Inc. offers a yield of 2.52% to investors and pays a quarterly dividend of $0.79 per share. Regeneron Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Gilead Sciences, Inc. pays out 805.23% of its earnings as a dividend.

Regeneron Pharmaceuticals, Inc. quarterly revenues are $3.8B, which are smaller than Gilead Sciences, Inc. quarterly revenues of $7.8B. Regeneron Pharmaceuticals, Inc.'s net income of $1.5B is lower than Gilead Sciences, Inc.'s net income of $3.1B. Notably, Regeneron Pharmaceuticals, Inc.'s price-to-earnings ratio is 18.80x while Gilead Sciences, Inc.'s PE ratio is 19.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regeneron Pharmaceuticals, Inc. is 6.07x versus 5.42x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 38.89% compared to Regeneron Pharmaceuticals, Inc.'s net margin of 21.47%. Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37% beat Johnson & Johnson's return on equity of 33.27%.

Regeneron Pharmaceuticals, Inc. has a consensus price target of $789.90, signalling upside risk potential of 0.6%. On the other hand Johnson & Johnson has an analysts' consensus of $209.29 which suggests that it could grow by 1.71%. Given that Johnson & Johnson has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Johnson & Johnson is more attractive than Regeneron Pharmaceuticals, Inc..

Regeneron Pharmaceuticals, Inc. has a beta of 0.369, which suggesting that the stock is 63.095% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.296%.

Regeneron Pharmaceuticals, Inc. has a quarterly dividend of $0.88 per share corresponding to a yield of 0.45%. Johnson & Johnson offers a yield of 2.5% to investors and pays a quarterly dividend of $1.30 per share. Regeneron Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Regeneron Pharmaceuticals, Inc. quarterly revenues are $3.8B, which are smaller than Johnson & Johnson quarterly revenues of $24B. Regeneron Pharmaceuticals, Inc.'s net income of $1.5B is lower than Johnson & Johnson's net income of $5.2B. Notably, Regeneron Pharmaceuticals, Inc.'s price-to-earnings ratio is 18.80x while Johnson & Johnson's PE ratio is 19.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regeneron Pharmaceuticals, Inc. is 6.07x versus 5.41x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of 38.89% compared to Regeneron Pharmaceuticals, Inc.'s net margin of 31.72%. Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37% beat Eli Lilly & Co.'s return on equity of 106.26%.

Regeneron Pharmaceuticals, Inc. has a consensus price target of $789.90, signalling upside risk potential of 0.6%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,093.22 which suggests that it could grow by 2.01%. Given that Eli Lilly & Co. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Eli Lilly & Co. is more attractive than Regeneron Pharmaceuticals, Inc..

Regeneron Pharmaceuticals, Inc. has a beta of 0.369, which suggesting that the stock is 63.095% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

Regeneron Pharmaceuticals, Inc. has a quarterly dividend of $0.88 per share corresponding to a yield of 0.45%. Eli Lilly & Co. offers a yield of 0.56% to investors and pays a quarterly dividend of $1.50 per share. Regeneron Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Regeneron Pharmaceuticals, Inc. quarterly revenues are $3.8B, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Regeneron Pharmaceuticals, Inc.'s net income of $1.5B is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Regeneron Pharmaceuticals, Inc.'s price-to-earnings ratio is 18.80x while Eli Lilly & Co.'s PE ratio is 53.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regeneron Pharmaceuticals, Inc. is 6.07x versus 16.44x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of 38.89% compared to Regeneron Pharmaceuticals, Inc.'s net margin of 33.68%. Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37% beat Merck & Co., Inc.'s return on equity of 39.63%.

Regeneron Pharmaceuticals, Inc. has a consensus price target of $789.90, signalling upside risk potential of 0.6%. On the other hand Merck & Co., Inc. has an analysts' consensus of $110.04 which suggests that it could grow by 4.76%. Given that Merck & Co., Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Merck & Co., Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

Regeneron Pharmaceuticals, Inc. has a beta of 0.369, which suggesting that the stock is 63.095% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.

Regeneron Pharmaceuticals, Inc. has a quarterly dividend of $0.88 per share corresponding to a yield of 0.45%. Merck & Co., Inc. offers a yield of 3.12% to investors and pays a quarterly dividend of $0.85 per share. Regeneron Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Regeneron Pharmaceuticals, Inc. quarterly revenues are $3.8B, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Regeneron Pharmaceuticals, Inc.'s net income of $1.5B is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Regeneron Pharmaceuticals, Inc.'s price-to-earnings ratio is 18.80x while Merck & Co., Inc.'s PE ratio is 13.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regeneron Pharmaceuticals, Inc. is 6.07x versus 4.14x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.